MedPath

Acepodia's ACE1831 Receives FDA IND Clearance for IgG4-Related Disease Trial

• Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for investigation in IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment. • ACE1831 targets CD20-expressing cells and is designed as an off-the-shelf therapy, potentially reducing side effects associated with autologous CAR-T cell therapies. • A Phase 1b/2a study, in collaboration with Pfizer Ignite, will assess the safety and efficacy of ACE1831 in IgG4-RD patients, led by Dr. John Stone of Massachusetts General Hospital. • The trial aims to demonstrate that ACE1831 can achieve deeper B cell depletion than antibody drugs, potentially leading to longer remission in autoimmune diseases.

Acepodia, a clinical-stage biotechnology company, has announced FDA clearance of its Investigational New Drug (IND) application for ACE1831 in IgG4-related disease (IgG4-RD). This clearance allows Acepodia to initiate clinical trials for its lead candidate in this multi-organ, fibro-inflammatory autoimmune condition.

ACE1831: A Novel Approach to B Cell Depletion

ACE1831 is an allogeneic gamma delta T cell therapy candidate that targets CD20-expressing cells. It employs bioorthogonal chemistry to link CD20-targeting antibodies to gamma delta T cells, creating an off-the-shelf T cell therapy. This approach aims to improve scalability and reduce the risk of side effects often associated with autologous CAR-T cell therapies, such as T cell malignancies. ACE1831 is also currently in a Phase 1 dose escalation study for non-Hodgkin’s lymphoma (NHL).

Clinical Trial Details and Collaboration

The Phase 1b/2a study of ACE1831 will be conducted in collaboration with Pfizer Ignite. Dr. John Stone, MD, MPH, of Massachusetts General Hospital, a leading IgG4-RD researcher, will lead the study. The trial will evaluate the safety and efficacy of ACE1831 in patients with IgG4-RD.
Dr. Stone emphasized the importance of B cell depletion in managing IgG4-RD, noting the efficacy of rituximab in disease control. He expressed enthusiasm for ACE1831's potential for deeper B cell depletion, ease of use, and potentially fewer adverse effects compared to other cell-based approaches.

Rationale for ACE1831 in Autoimmune Disease

Acepodia's CEO, Dr. Sonny Hsiao, stated the hope that ACE1831 can deliver deeper B cell depletion than antibody drugs, which is critical for longer remission in autoimmune diseases. This approach is based on observations of clinical benefits of CAR-T in autoimmune diseases.

About IgG4-Related Disease

IgG4-RD is a systemic fibro-inflammatory condition that can affect multiple organs, leading to significant morbidity. Current treatments often involve B cell depletion strategies, but there remains a need for more effective and less toxic therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Intas Pharma Receives CDSCO Panel Nod for Aflibercept Biosimilar DME Trial

Intas Pharmaceuticals gains CDSCO approval for a Phase III trial comparing its aflibercept biosimilar with Eylea in diabetic macular edema (DME) patients.
The study will evaluate the efficacy, safety, and immunogenicity of Intas' aflibercept intravitreal injection against Eylea.

OncoC4's AI-081, a PD-1/VEGF Bispecific Antibody, Receives FDA IND Clearance for Advanced Solid Tumors

OncoC4 announced FDA clearance of its IND application for AI-081, a bispecific antibody targeting PD-1 and VEGF, for treating advanced solid tumors.
AI-081 leverages high-affinity anti-PD1 and anti-VEGF antibodies, demonstrating superior PD-1 blockade and anti-tumor activity in preclinical studies.

FDA Approves PTC Therapeutics' Gene Therapy Kebilidi for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi), a gene therapy developed by PTC Therapeutics, for treating AADC deficiency in adult and pediatric patients.
Kebilidi is the first FDA-approved gene therapy for AADC deficiency, a rare genetic disorder affecting neurotransmitter production and causing severe developmental delays.

Acepodia's ACE1831 Receives FDA IND Clearance for IgG4-Related Disease

Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for IgG4-related disease, marking Acepodia's entry into autoimmune disease therapeutics.
ACE1831 targets CD20-expressing cells using Antibody-Cell Conjugation (ACC) technology, offering a potentially scalable and safer alternative to autologous CAR-T cell therapies.

Adicet Bio's ADI-001 Demonstrates Promising CAR T-Cell Activation in Autoimmune Diseases

Adicet Bio presented clinical biomarker data for ADI-001, an off-the-shelf gamma delta CAR T cell therapy, at the ACR Convergence 2024, showcasing its potential in treating autoimmune diseases.
The data revealed robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue, with CAR T cell activation levels ranging from 27-64% at the 1E9 dose.

Acepodia's ACE1831 Receives FDA IND Clearance for IgG4-Related Disease

Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment.
ACE1831 targets CD20-expressing cells and is designed as an off-the-shelf therapy, potentially reducing side effects associated with autologous CAR-T cell therapies.

Appili Therapeutics Gains FDA Alignment on ATI-1801 Development for Leishmaniasis

Appili Therapeutics has received positive feedback from the FDA regarding its development strategy for ATI-1801, a topical antiparasitic product.
ATI-1801 is being developed for the treatment of leishmaniasis, a disfiguring parasitic disease with significant unmet medical needs.

Appili Therapeutics Receives Positive FDA Feedback on ATI-1801 Development for NDA Submission

Appili Therapeutics announced that the FDA has provided positive feedback on its development strategy for ATI-1801, a topical antiparasitic product.
The FDA's feedback aligns with the requirements for a New Drug Application (NDA) submission, marking a significant milestone for the drug's development.

Adicet's ADI-001 CAR-T Therapy Expands Clinical Trial to Include Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio's ADI-001, a CAR-engineered gamma delta T-cell therapy, has received FDA clearance to expand its Phase 1 trial to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
The Phase 1 trial will now include arms for lupus nephritis (LN) and SLE, systemic sclerosis (SSc), antineutrophil cytoplasmic autoantibody associated vasculitis (AAV), and IIM/SPS.

CD Biopharma's CD-001 Receives FDA Clearance for Phase 1 Trial in Oncology

CD Biopharma's CD-001, a bispecific fusion protein, has been cleared by the FDA for a Phase 1 clinical trial.
CD-001 targets PD-1-positive, CD8-positive T cells using an anti-PD-1 antibody and an engineered IL-21 mutant.

Reference News

[1]
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 ...
biospace.com · Nov 15, 2024

Acepodia receives FDA IND clearance for ACE1831, an allogeneic gamma delta T cell therapy targeting CD20-expressing cell...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy